Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Public ClinicalTrials.gov record NCT03027609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.
Study identification
- NCT ID
- NCT03027609
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 158 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2017 (Actual)
- Primary completion
- Apr 25, 2019 (Actual)
- Completion
- Apr 25, 2019 (Actual)
- Last update posted
- Mar 17, 2022
2017 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 1 | Sacramento | California | 95814 | — |
| Research Site 2 | San Diego | California | 92103 | — |
| Research Site 3 | Jacksonville | Florida | 32209 | — |
| Research Site 4 | Tampa | Florida | 33606 | — |
| Research Site 5 | Chicago | Illinois | 60611 | — |
| Research Site 6 | Lexington | Kentucky | 40536 | — |
| Research Site 7 | Detroit | Michigan | 48201 | — |
| Research Site 8 | Detroit | Michigan | 48201 | — |
| Research Site 9 | Royal Oak | Michigan | 48073 | — |
| Research Site 10 | St Louis | Missouri | 63110 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Hackensack | New Jersey | 02601 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Columbus | Ohio | 43215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03027609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2022 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03027609 live on ClinicalTrials.gov.